BONZO Antibody from ROCKLAND IMMUNOCHEMICALS INC.
Search, find, compare suppliers for anti-BONZO antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | BONZO |
| Clone | polyclonal |
| Host Species | Rabbit |
| Reactive Species | human |
| Isotype | n/a |
| Format | DEAE purified |
| Size | 100 µg |
| Concentration | 1 mg/mL |
| Applications | ELISA, Western Blot |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Anti-Bonzo Antibody is purified by DEAE purification methods. Cross reactivity with Bonzo from other sources has not been determined. Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) require coreceptors, in addition to CD4, to infect target cells. Some G protein-coupled receptors including CCR5, CXCR4, CCR3, and CCR2b in the chemokine receptor family have been identified as HIV coreceptors. An orphan G protein-coupled receptor was recently cloned and designated Bonzo, STRL33 and TYMSTR, and identified as HIV and SIV coreceptor. Bonzo/STRL33 is used by SIV, HIV-2 and HIV-1. The messenger RNA of Bonzo/STRL33 is expressed in lymphoid tissues and activated peripheral blood lymphocytes. |
| Immunogen | Anti-Bonzo antibody was prepared from whole rabbit serum produced by repeated immunizations with a 20 amino acid peptide near the C-terminus of human Bonzo. |
| Other Names | Bonzo Antibody, BONZO, CD186, STRL33, TYMSTR, BONZO, C-X-C chemokine receptor type 6, CDw186, CXC-R6 |
| Gene, Accession # | CXCR6, Gene ID: 10663, NCBI: AAB64221, UniProt: O00574 |
| Catalog # | 200-401-Z82 |
| Price | $475 |
| Order / More Info | BONZO Antibody from ROCKLAND IMMUNOCHEMICALS INC. |
| Product Specific References | n/a |
ROCKLAND IMMUNOCHEMICALS INC.
ROCKLAND IMMUNOCHEMICALS INC.
PO Box 5199
Limerick PA 19468
P: 484-791-3823
P: 800.656.7625
F: 484.369.8654
orders@rockland.com
Technical Support: tech@rockland.com
https://www.rockland.com/
Profile of ROCKLAND IMMUNOCHEMICALS INC.
Return to Antibodies